[Federal Register Volume 82, Number 12 (Thursday, January 19, 2017)]
[Notices]
[Pages 6644-6645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-01143]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-890 (Remand)]


Certain Sleep-Disordered Breathing Treatment Systems and 
Components Thereof; Commission Determination to Review In-Part a Final 
Initial Determination on Remand, and on Remand To Affirm With 
Modification; Vacatur of Suspended Remedial Orders; and Termination of 
the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined to review in-part the presiding 
Administrative Law Judge's (``ALJ'') final initial determination on 
remand (``RID'') for the limited purpose of modifying pages 20-21 and 
24 of the RID. The Commission has also determined to vacate the issued 
remedial orders, which are currently suspended.

FOR FURTHER INFORMATION CONTACT: Panyin A. Hughes, Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-3042. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its Internet server (https://www.usitc.gov). The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on August 23, 2013, based on a complaint filed by ResMed Corporation of 
San Diego, California; ResMed Incorporated of San Diego, California; 
and ResMed Limited of New South Wales, Australia (collectively, 
``ResMed''). 78 FR 52564 (Aug. 23, 2013). The complaint alleged 
violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in 
the importation into the United States, the sale for importation, and 
the sale within the United States after importation of certain sleep-
disordered breathing treatment systems and components thereof that 
infringe one or more of claims 32-37, 53, 79, 80, and 88 of U.S. Patent 
No. 7,997,267 (``the '267 patent''); claims 1-7 of U.S. Patent No. 
7,614,398 (``the '398 patent''); claim 1 of U.S. Patent No. 7,938,116 
(``the '116 patent''); claims 30, 37, and 38 of U.S. Patent No. 
7,341,060 (the '060 patent); claims 1, 3, 5, 11, 28, 30, 31, and 56 of 
U.S. Patent No. 8,312,883 (``the '883 patent''); claims 1, 3, 6, 7, 9, 
29, 32, 35, 40, 42, 45, 50, 51, 56, 59, 89, 92, 94, and 96 of U.S. 
Patent No. 7,178,527 (the '527 patent); claims 19-24, 26, 29-36, and 
39-41 of U.S. Patent No. 7,950,392 (the '392 patent); and claims 13, 
15, 16, 26-28, 51, 52, and 55 of U.S. Patent No 7,926,487 (``the '487 
patent''). The following patents are collectively referred to as the 
mask patents: the '527 patent; the '392 patent; the '267 patent; the 
'060 patent; and the'883 patent. The notice of investigation named the 
following respondents: BMC Medical Co., Ltd. of Beijing, China; 3B 
Medical, Inc. of Lake Wales, Florida; and 3B Products, L.L.C., of Lake 
Wales, Florida (collectively ``BMC''). The Office of Unfair Import 
Investigations (``OUII'') participated in the investigation.
    On January 9, 2014, the ALJ issued an initial determination 
(``ID'') granting a motion by ResMed to amend the complaint and notice 
of investigation to substitute U.S. Patent No. RE 44,453 (``the '453 
patent'') for the '398 patent and to terminate the investigation as to 
the '398 patent. See Order No. 7 (Jan. 9, 2014). The Commission 
determined not to review the ID. See Commission Notice of Non-Review 
(Feb. 10, 2014); 79 FR 9000-01 (Feb. 14, 2014).
    On February 24, 2014, the ALJ issued an ID granting a motion by 
ResMed to withdraw its allegations with respect to the '116 patent. See 
Order No. 11 (Feb. 24, 2014). The Commission determined not to review 
the ID. See Commission Notice of Non-Review (March 11, 2014). On March 
18, 2014, the ALJ granted a motion by ResMed to terminate the 
investigation as to claims 26-28 of the '487 Patent. See Order No. 20 
(Mar 18, 2012). The Commission determined not to review the ID. See 
Commission Notice of Non-Review (Apr. 29, 2014).
    On August 21, 2014, the ALJ issued a final ID, finding a violation 
of section 337 by BMC with respect to certain asserted claims of the 
'392, '267, '060, '883, '527, and '453 patents. The ALJ found no 
violation of section 337 with respect to the asserted claims of the 
'487 patent.
    On September 3, 2014, the parties filed petitions for review of the 
ID. On September 11, 2014, the parties filed responses to the petitions 
for review.
    On October 16, 2014, the Commission determined to review the final 
ID in part. 79 FR 63163-65 (Oct. 22, 2014). On review, the Commission 
determined to affirm the ALJ's finding of violation of section 337. The 
Commission, however, found the '453 patent invalid for anticipation. 
Having found a violation of section 337, the Commission determined that 
the appropriate form of relief was (1) a limited exclusion order 
prohibiting the unlicensed entry of sleep-disordered breathing 
treatment systems and components thereof that infringe one or more of 
claims 1, 9, 32, 89, and 92 of the '527 patent; claims 19, 21, 29, 32, 
and 36 of the '392 patent; claims 32, 33, 34, and 53 of the '267 
patent; claims 30, 37, and 38 of the '060 patent; and claims 1, 3, 5, 
11, 28, 30, 31, and 56 of the '883 patent that are manufactured by, or 
on behalf of, or are imported by or on behalf of BMC Medical Co., Ltd., 
3B Medical, Inc., or 3B Products L.L.C. or any of their affiliated 
companies, parents, subsidiaries, agents, or other related business 
entities, or their successors or assigns, except for service

[[Page 6645]]

and replacement parts for customers that purchased their covered 
products prior to the date the exclusion order becomes final; and (2) 
cease and desist orders prohibiting domestic respondents BMC Medical 
Co., Ltd., 3B Medical, Inc. from conducting any of the following 
activities in the United States: Importing, selling, marketing, 
advertising, distributing, transferring (except for exportation), and 
soliciting U.S. agents or distributors for, sleep-disordered breathing 
treatment systems and components thereof covered by claims 1, 9, 32, 
89, and 92 of the '527 patent; claims 19, 21, 29, 32, and 36 of the 
'392 patent; claims 32, 33, 34, and 53 of the '267 patent; claims 30, 
37, and 38 of the '060 patent; and claims 1, 3, 5, 11, 28, 30, 31, and 
56 of the '883 patent.
    On February 18, 2015, ResMed filed a notice of appeal in the U.S. 
Court of Appeals for the Federal Circuit, seeking review of the 
Commission's determination as to the '453 patent (Appeal No. 2015-
1360). On April 14, 2015, BMC filed a notice of appeal in the Federal 
Circuit, seeking review of the Commission's domestic industry 
determination as well as the Commission's finding that prior art does 
not render the asserted claims of the '267 patent invalid for 
obviousness (Appeal No. 2015-1576). The Court consolidated the two 
appeals on April 23, 2015.
    On March 16, 2016, the parties jointly moved to dismiss ResMed's 
appeal as to the '453 patent. On March 17, 2016, the Commission moved 
to remand BMC's appeal in light of intervening domestic industry 
precedent in Lelo Inc. v. International Trade Commisson, 789 F.3d 879 
(Fed. Cir. 2015). On March 29, 2016, the Court granted the motion to 
dismiss ResMed's appeal. On April 22, 2016, the Court granted the 
Commission's remand motion.
    On May 12, 2016, the Commission issued a notice suspending the 
remedial orders in place during the pendency of the remand proceedings. 
81 FR 31254-55 (May 18, 2016). The Commission also issued an order 
asking the parties to comment on further proceedings. On June 8, 2016, 
the parties submitted initial comments. The parties filed responses on 
July 15, 2016. On August 16, 2016, the Commission issued an order 
remanding the investigation to the ALJ to: (1) Apply the Federal 
Circuit's intervening domestic industry precedent in Lelo to the 
existing record (as to the mask patents, the only patents remaining); 
and (2) issue an RID on remand as to violation.
    On November 10, 2016, the ALJ issued the RID finding that ResMed 
failed to establish the existence of a domestic industry that practices 
the mask patents. RID at 1. No petitions for review were received.
    Having examined the record of this investigation, the Commission 
has determined to review in-part the RID for the limited purpose of 
modifying pages 20-21 and 24 of the RID. The Commission does not adopt 
the RID's statements that ``the amount a complainant spends to purchase 
components manufactured in the United States is immaterial to the 
economic prong analysis'' (RID at 20-21) or that evidence of payments 
to domestic suppliers is ``per se insufficient to include in the 
quantitative analysis.'' RID at 24. The Commission has determined to 
otherwise not review the RID. The Commission has determined to vacate 
the suspended remedial orders. The investigation is terminated.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: January 12, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017-01143 Filed 1-18-17; 8:45 am]
 BILLING CODE 7020-02-P